104 related articles for article (PubMed ID: 22831885)
1. Glucagon-like peptide-1 agonist exendin-4 leads to reduction of weight and caloric intake in a rat model of hypothalamic obesity.
Elfers CT; Simmons JH; Roth CL
Horm Res Paediatr; 2012; 78(1):47-53. PubMed ID: 22831885
[TBL] [Abstract][Full Text] [Related]
2. Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats.
Reidelberger RD; Haver AC; Apenteng BA; Anders KL; Steenson SM
Obesity (Silver Spring); 2011 Jan; 19(1):121-7. PubMed ID: 20559304
[TBL] [Abstract][Full Text] [Related]
3. Treatment with glucagon-like Peptide-1 agonist exendin-4 in a patient with hypothalamic obesity secondary to intracranial tumor.
Simmons JH; Shoemaker AH; Roth CL
Horm Res Paediatr; 2012; 78(1):54-8. PubMed ID: 22831918
[TBL] [Abstract][Full Text] [Related]
4. Exenatide and weight loss.
Bradley DP; Kulstad R; Schoeller DA
Nutrition; 2010 Mar; 26(3):243-9. PubMed ID: 20152707
[TBL] [Abstract][Full Text] [Related]
5. Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing.
Roan JN; Cheng HN; Young CC; Lee CJ; Yeh ML; Luo CY; Tsai YS; Lam CF
J Surg Res; 2017 Feb; 208():93-103. PubMed ID: 27993221
[TBL] [Abstract][Full Text] [Related]
6. Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats.
Barrera JG; D'Alessio DA; Drucker DJ; Woods SC; Seeley RJ
Diabetes; 2009 Dec; 58(12):2820-7. PubMed ID: 19741167
[TBL] [Abstract][Full Text] [Related]
7. The Food Environment, Preference, and Experience Modulate the Effects of Exendin-4 on Food Intake and Reward.
Mella R; Schmidt CB; Romagnoli PP; Teske JA; Perez-Leighton C
Obesity (Silver Spring); 2017 Nov; 25(11):1844-1851. PubMed ID: 29086500
[TBL] [Abstract][Full Text] [Related]
8. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures.
Mack CM; Moore CX; Jodka CM; Bhavsar S; Wilson JK; Hoyt JA; Roan JL; Vu C; Laugero KD; Parkes DG; Young AA
Int J Obes (Lond); 2006 Sep; 30(9):1332-40. PubMed ID: 16534527
[TBL] [Abstract][Full Text] [Related]
9. Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents.
Trevaskis JL; Sun C; Athanacio J; D'Souza L; Samant M; Tatarkiewicz K; Griffin PS; Wittmer C; Wang Y; Teng CH; Forood B; Parkes DG; Roth JD
Diabetes Obes Metab; 2015 Jan; 17(1):61-73. PubMed ID: 25204356
[TBL] [Abstract][Full Text] [Related]
10. The role of clusterin on pancreatic beta cell regeneration after exendin-4 treatment in neonatal streptozotocin administrated rats.
Kaya-Dagistanli F; Ozturk M
Acta Histochem; 2013 Jul; 115(6):577-86. PubMed ID: 23351716
[TBL] [Abstract][Full Text] [Related]
11. GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases.
Zoicas F; Droste M; Mayr B; Buchfelder M; Schöfl C
Eur J Endocrinol; 2013 May; 168(5):699-706. PubMed ID: 23392214
[TBL] [Abstract][Full Text] [Related]
12. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice.
Talsania T; Anini Y; Siu S; Drucker DJ; Brubaker PL
Endocrinology; 2005 Sep; 146(9):3748-56. PubMed ID: 15932924
[TBL] [Abstract][Full Text] [Related]
13. Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*.
Patel V; Joharapurkar A; Gandhi T; Patel K; Dhanesha N; Kshirsagar S; Dhote V; Detroja J; Bahekar R; Jain M
J Diabetes; 2013 Jun; 5(2):163-71. PubMed ID: 22830490
[TBL] [Abstract][Full Text] [Related]
14. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK.
Beiroa D; Imbernon M; Gallego R; Senra A; Herranz D; Villarroya F; Serrano M; Fernø J; Salvador J; Escalada J; Dieguez C; Lopez M; Frühbeck G; Nogueiras R
Diabetes; 2014 Oct; 63(10):3346-58. PubMed ID: 24917578
[TBL] [Abstract][Full Text] [Related]
15. The GLP-1 agonist exendin-4 attenuates self-administration of sweetened fat on fixed and progressive ratio schedules of reinforcement in rats.
Bernosky-Smith KA; Stanger DB; Trujillo AJ; Mitchell LR; España RA; Bass CE
Pharmacol Biochem Behav; 2016 Mar; 142():48-55. PubMed ID: 26701752
[TBL] [Abstract][Full Text] [Related]
16. The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size.
Scott KA; Moran TH
Am J Physiol Regul Integr Comp Physiol; 2007 Sep; 293(3):R983-7. PubMed ID: 17581835
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 regulation of carbohydrate intake is differentially affected by obesogenic diets.
Pritchett CE; Hajnal A
Obesity (Silver Spring); 2012 Feb; 20(2):313-7. PubMed ID: 22134200
[TBL] [Abstract][Full Text] [Related]
18. Effects of leptin replacement alone and with exendin-4 on food intake and weight regain in weight-reduced diet-induced obese rats.
Reidelberger R; Haver A; Chelikani PK; Apenteng B; Perriotte-Olson C; Anders K; Steenson S; Blevins JE
Am J Physiol Endocrinol Metab; 2012 Jun; 302(12):E1576-85. PubMed ID: 22510712
[TBL] [Abstract][Full Text] [Related]
19. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats.
Rodriquez de Fonseca F; Navarro M; Alvarez E; Roncero I; Chowen JA; Maestre O; Gómez R; Muñoz RM; Eng J; Blázquez E
Metabolism; 2000 Jun; 49(6):709-17. PubMed ID: 10877194
[TBL] [Abstract][Full Text] [Related]
20. Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor.
Washington MC; Raboin SJ; Thompson W; Larsen CJ; Sayegh AI
Brain Res; 2010 Jul; 1344():124-33. PubMed ID: 20452329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
